World Vaccine and Immunotherapy Congress 2021 Agenda

 

San Diego, 30 November 2021 - 2 December 2021

Schedule

Create your personal agenda –check the favourite icon

Nov 3008:30
Conference pass

Keynote panel: Tackling future viral pandemics – a holistic view

Keynotes
  • Use of antiviral drugs to reduce morbidity and mortality
  • Global-preparedness programmes that potentiate
    • ability to rapidly test existing and newly designed antiviral drugs (small molecule and neutralizing mAbs)
    • development of safe, effective, easy-to-produce, reasonably priced vaccines
  • Speed of research to serve as a template for future viral pandemics
Nov 3009:30
Conference pass

Keynote presentation: Epidemiological surveillance to inform global preparedness and response

Keynotes
  • How are viral, ecological, and environmental factors used to determine which viruses pose the greatest threat to human health?
  • Understanding the virus-host ecology of emerging viruses
  • Drivers of zoonotic and cross-species transmission
Nov 3010:00
Conference pass

Keynote panel: Pan-coronavirus vaccines – feasibility & funding

Keynotes
  • Renewed interest in the development of pan-coronavirus vaccines
  • Implications for the next pandemic - baseline levels of cross-reactivity to lower clinical severity & prevent hospitalisations – how much is enough protection?
  • Multiple targets
  • Structural vaccinology & other approaches
  • Cost of manufacture? Is developing the nanoparticle-based vaccine same cost as allum-based vaccines?
Additional panellists TBC
Nov 3011:00
Conference pass

Exhibition & Partnering Break

Keynotes
Tea, Coffee and Refreshments served in the exhibition areaOne-to-one networking meetings
Nov 3011:45
Conference pass

Socially Distanced Roundtables

Keynotes
Interactive discussions with like-minded peers tackling the similar challenges in vaccine, antibody and immunotherapy development. Max 20 per table. Sign-up in advance.
  • AMR – Trial site selection – Speaker TBC
  • Emergent Biosolutions – Increasing consumer acceptance of travel vaccine recommendations - Speaker TBC
Nov 3014:10
Conference pass

First Multitope COVID-19 vaccine, from mice to man

Infectious Disease Vaccines
Nov 3014:10
Conference pass

Enhancing anti-PD-1 immune responses in solid tumors

Cancer Immunotherapy
Nov 3014:10
Conference pass

Accelerating therapeutics & biomarker discovery through single-cell proteomics - Title TBC

Immune Profiling & Translational Science
Senior Representative, IsoPlexis
Nov 3014:25
Conference pass

COVID-19 & Influenza vaccine development using MIMIX platform

Infectious Disease Vaccines
Nov 3014:40
Conference pass

Clinical updates in the development of an oral COVID-19 vaccine candidate

Infectious Disease Vaccines
Nov 3014:40
Conference pass

Discovery & development of antibodies to relieve immunosuppression in the tumor microenvironment

Cancer Immunotherapy
Nov 3014:40
Conference pass

Systems vaccinology enabled by multiomic single cell immune profiling

Immune Profiling & Translational Science
Senior Representative, 10X Genomics
Nov 3014:55
Conference pass

xMAP platform technology combining low- and high-plex capabilities - Title TBC

Immune Profiling & Translational Science
Senior Representative, Luminex
Nov 3015:10
Conference pass

CORAL COVID-19 Vaccine – inducing immunity against spike & other viral antigens

Infectious Disease Vaccines
Nov 3015:10
Conference pass

Panel: What does the future look like for the development, validation & execution of biomarkers for response, resistance & disease monitoring

Immune Profiling & Translational Science
  • How can we improve early cancer screening? What is early – stage 1? Or stage 1-3?
  • Difference between screening and detection?
  • Alternative biomarker sources - Exosomes / microbiome-based / ADCs
  • Challenges and opportunities in novel biomarker sources
    • Extraction challenges
    • Reimbursement issues (companion Dx vs early detection not reimbursed)
  • Multi-cancer detection? A valuable proposition?
Additional panellists TBC
Nov 3015:25
Conference pass

Evaluation of covid-19 vaccines with saponin vaccine adjuvant TQL1055

Infectious Disease Vaccines
Senior Representative, Adjuvance Technologies
Nov 3015:40
Conference pass

VLP-based COVID-19 vaccine development

Infectious Disease Vaccines
Nov 3016:40
Conference pass

Animal Study Reproducibility: Problems and Solutions -15min

Infectious Disease Vaccines
Nov 3016:40
Conference pass

Using Dengue fever to treat cancer

Cancer Immunotherapy
Nov 3016:40
Conference pass

Microbiome driven liquid biopsy for early cancer detection

Immune Profiling & Translational Science
Nov 3016:55
Conference pass

The impact of COVID vaccine work on research sites and the future of this from a site’s perspective

Infectious Disease Vaccines
Nov 3017:10
Conference pass

Ensuring supply during decentralized vaccine trials

Infectious Disease Vaccines
Senior Representative, Marken
Nov 3017:10
Conference pass

Personalised oncolytic adenovirus therapies

Cancer Immunotherapy
Senior Representative, Virica
Nov 3017:10
Conference pass

Panel: Overcoming T-cdell exhaustion in infection and cancer

Immune Profiling & Translational Science
Additional panellists TBC
Nov 3017:40
Conference pass

Critical role of protein reagents in vaccine development

Infectious Disease Vaccines
Nov 3017:40
Conference pass

Oncolytic viruses mechanism of action and interaction with immunomodulatory agents

Cancer Immunotherapy

Create your personal agenda –check the favourite icon

Dec 109:00
Conference pass

Keynote panel: Moving liquid biopsies into the clinic

Keynotes
  • Are we moving more towards blood-based approaches over tissue-based approaches? What have been the challenges with this?
    • What is the best use of ctDNA? Selection? Monitoring? Early detection?
  • Future applications
  • Key issues and gaps in technology – what are the best types of technology? Personalised? General?
    • Is this technology ready for implementation? -
  • Clinical trial methodologies and logistics for integrating liquid biopsies into clinical workflow
  • What should be done with positive readings for early detection?
Dec 110:00
Conference pass

Keynote panels & Interviews: Raising capital – has the pandemic reignited interest in vaccine & immunotherapy biotechs?

Keynotes
  • What has been the experience of both investors and vaccine & immunotherapy biotechs in raising capital during the pandemic?
  • Will interest be sustained? What are the advantages and disadvantages of renewed interest?
  • Will success of mRNA inspire confidence in other vaccine & immunotherapy modalities & platforms?
Additional panellists TBC
Dec 111:30
Conference pass

Chair’s opening remarks

Cancer Immunotherapy
Dec 111:40
Conference pass

Broad-spectrum pneumococcal conjugate vaccine development

Infectious Disease Vaccines
Dec 111:40
Conference pass

Panel: Are neoantigens living up to their initial promise? What questions remain unanswered?

Cancer Immunotherapy
  • Addressing ongoing challenges in NeoAg identification / verification
  • Some NeoAgs more immunogenic than others – what role do different platform technologies play?
  • What elements of the immune cycle should we look more closely at/ need to be addressed?
  • Rational combination with other IO?
  • Evidence for inhibitory antigens and their role?
Dec 111:40
Conference pass

Novel T-cell tests for the early detection of infectious disease & cancer

Immune Profiling & Translational Science
Senior Representative, Adaptive Biotechnologies
Dec 112:10
Conference pass

Challenges and opportunities in developing next generation PCVs

Infectious Disease Vaccines
  • Optimal vaccine formulation, limitations of conventional chemistry and vaccination schedule for different settings and high-risk populations
  • Impact of serotype replacement following PCV use
  • Transmission in high-burden settings
  • Carrier suppression - understanding the immunological markers of long-term protection against carriage
Additional panellists TBC
Krishna Prasad, Founder, Citranvi Biosciences LLC
Dec 112:10
Conference pass

RT-qPCR, sequencing, and T cell immunity testing supporting SARS-CoV-2 vaccine clinical trials

Immune Profiling & Translational Science
Senior Representative, Eurofins Viracor
Dec 112:25
Conference pass

In depth functional characterization of novel monoclonal antibodies to the SARS-CoV2 virus

Immune Profiling & Translational Science
Dec 112:40
Conference pass

Extrapolation of epitope prediction from IO onto infectious diseases: lessons learned

Cancer Immunotherapy
Dec 112:40
Conference pass

Development of a novel assay to assess the avidity of dengue virus-specific antibodies elicited in response to a tetravalent dengue vaccine

Immune Profiling & Translational Science
David Dominguez, Research Associate, Takeda
Dec 114:10
Conference pass

SARS-CoV-2 Immunity: What have we learnt about characteristics of the immune response to Covid-19 infection pre & post vaccination?

Immune Profiling & Translational Science
  • Adaptive responses to in natural infection and vaccination
  • Durability of those responses
  • Adaptive responses to variants
  • Pan coronavirus responses addressed experimentally
Additional panellists TBC
Dec 114:40
Conference pass

High-throughput antibody production for vaccine & immunotherapy R&D

Infectious Disease Vaccines
Senior Representative, SinoBiological
Dec 114:55
Conference pass

Scalable, host independent, continuous flow mRNA vaccine manufacturing

Infectious Disease Vaccines
Dec 115:10
Conference pass

Tailoring vaccine manufacturing strategies to multiple platforms

Infectious Disease Vaccines
Senior Representative, Sartorius Stedim Biotech
Dec 115:10
Conference pass

Development of eVLP platform for viral associated cancers

Cancer Immunotherapy
Senior Representative, VBI Vaccines
Dec 115:10
Conference pass

SARS-CoV-2 Assay development

Immune Profiling & Translational Science
Senior Representative, Luminex
Dec 115:40
Conference pass

Avoiding bottlenecks and scale-up of viral vaccines

Infectious Disease Vaccines
Dec 115:40
Conference pass

Combining real-time impedance monitoring and live cell imaging to rapidly identify and characterize antiviral drugs and neutralizing antibodies

Immune Profiling & Translational Science
Dec 116:40
Conference pass

Use of needle-free injection technology in vaccine delivery

Infectious Disease Vaccines
Dec 116:40
Conference pass

Hapentized vaccines for viral diseases & cancer

Cancer Immunotherapy
Dec 116:40
Conference pass

Viral vector characterization - Title TBC

Immune Profiling & Translational Science
Dec 116:55
Conference pass

Patch technology for vaccine delivery

Infectious Disease Vaccines
Dec 117:25
Conference pass

Use of patch technology for influenza vaccines

Infectious Disease Vaccines

Create your personal agenda –check the favourite icon

Dec 209:00
Conference pass

Keynote Panel: How has our understanding of resistance in oncology evolved?

Keynotes
  • How do we think of resistance phenotypes?
  • What are the major mechanisms of resistance?
Additional panellists TBC
Dec 210:00
Conference pass

Keynote panel: US Immunization Policy – what have we learnt that could better prepare us for the next public health crisis

Keynotes
  • How can we improve access in the USA?
  • Preparedness for mass immunizations & follow through – is USA ready for future pandemics & general adult vaccines?
  • Maintaining immunization registries
  • Payment structure for seniors – out of pocket costs / Medicare part B&D
  • IP issues? Will this set a president? - Topic TBC based on current events
  • Challenges in converting immunization policy recommendations into legislation
  • What were the economic implications of the pandemic as a whole – what was the cost of illness?
  • What have we learned from vaccine programs about improving uptake and bolster confidence?
  • How do we build a more resilient public health infrastructure?
Dec 211:40
Conference pass

Emerging exosome-based vaccine platform – targeting infectious diseases and cancer

Cancer Immunotherapy
Dec 212:10
Conference pass

Live attenuated recombinant vaccines for RSV and COVID-19

Infectious Disease Vaccines
Dec 214:10
Conference pass

Safety surveillance cohort studies of vaccinia vaccine among military personnel

Infectious Disease Vaccines
Senior Representative, Emergent Biosolutions
Dec 214:40
Conference pass

Development of Lassa, CHIKV & MERS CoV vaccines using measles viral vector platform

Infectious Disease Vaccines
Dec 215:10
Conference pass

Design and evaluation of vaccines against hemorrhagic fevers using the MVA-VLP platform

Infectious Disease Vaccines
last published: 07/Oct/21 09:45 GMT